skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 126,648  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
Material Type:
Article
Add to My Research

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

Cancer discovery, 2015-08, Vol.5 (8), p.860-877

2015 American Association for Cancer Research. ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.CD-14-1236 ;PMID: 26069186

Full text available

2
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer
Material Type:
Article
Add to My Research

Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer

Cochrane database of systematic reviews, 2015-03, Vol.2015 (3), p.CD011430-CD011430 [Peer Reviewed Journal]

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;ISSN: 1469-493X ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011430 ;PMID: 25730344

Full text available

3
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial
Material Type:
Article
Add to My Research

Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial

Thorax, 2017-09, Vol.72 (9), p.825-831 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2016-209825 ;PMID: 28377492

Full text available

4
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-02, Vol.40 (6), p.586-597 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.21.01497 ;PMID: 34985920

Full text available

5
Lung cancer: current therapies and new targeted treatments
Material Type:
Article
Add to My Research

Lung cancer: current therapies and new targeted treatments

The Lancet (British edition), 2017-01, Vol.389 (10066), p.299-311 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 21, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)30958-8 ;PMID: 27574741 ;CODEN: LANCAO

Full text available

6
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Material Type:
Article
Add to My Research

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Mayo Clinic proceedings, 2019-08, Vol.94 (8), p.1623-1640 [Peer Reviewed Journal]

2019 Mayo Foundation for Medical Education and Research ;Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. ;COPYRIGHT 2019 Elsevier, Inc. ;ISSN: 0025-6196 ;EISSN: 1942-5546 ;DOI: 10.1016/j.mayocp.2019.01.013 ;PMID: 31378236

Full text available

7
The biology and management of non-small cell lung cancer
Material Type:
Article
Add to My Research

The biology and management of non-small cell lung cancer

Nature (London), 2018-01, Vol.553 (7689), p.446-454 [Peer Reviewed Journal]

COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Jan 25, 2018 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature25183 ;PMID: 29364287

Full text available

8
Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
Material Type:
Article
Add to My Research

Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Oncotarget, 2015-10, Vol.6 (32), p.32868-32877

Copyright: © 2015 Sestini et al. 2015 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.5210 ;PMID: 26451608

Full text available

9
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-03, Vol.39 (7), p.723-733 [Peer Reviewed Journal]

2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.20.01605 ;PMID: 33449799

Full text available

10
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177

Full text available

11
miR-Test: a blood test for lung cancer early detection
Material Type:
Article
Add to My Research

miR-Test: a blood test for lung cancer early detection

JNCI : Journal of the National Cancer Institute, 2015-06, Vol.107 (6), p.djv063-djv063 [Peer Reviewed Journal]

The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;Copyright Oxford Publishing Limited(England) Jun 2015 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djv063 ;PMID: 25794889 ;CODEN: JNCIEQ

Full text available

12
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Material Type:
Article
Add to My Research

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

The lancet oncology, 2014-02, Vol.15 (2), p.213-222 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 2014 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(13)70604-1 ;PMID: 24439929 ;CODEN: LANCAO

Full text available

13
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796

Full text available

14
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Material Type:
Article
Add to My Research

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907

Full text available

15
Integrating genomic features for non-invasive early lung cancer detection
Material Type:
Article
Add to My Research

Integrating genomic features for non-invasive early lung cancer detection

Nature (London), 2020-04, Vol.580 (7802), p.245-251 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;COPYRIGHT 2020 Nature Publishing Group ;Copyright Nature Publishing Group Apr 9, 2020 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2140-0 ;PMID: 32269342

Full text available

16
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Material Type:
Article
Add to My Research

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Cell, 2017-11, Vol.171 (6), p.1259-1271.e11 [Peer Reviewed Journal]

2017 The Francis Crick Institute ;Copyright © 2017 The Francis Crick Institute. Published by Elsevier Inc. All rights reserved. ;2017 The Francis Crick Institute 2017 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2017.10.001 ;PMID: 29107330

Full text available

17
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Material Type:
Article
Add to My Research

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809697 ;PMID: 30280658

Full text available

18
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1801005 ;PMID: 29658856

Full text available

19
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Material Type:
Article
Add to My Research

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Journal of clinical oncology, 2019-03, Vol.37 (7), p.537-546 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.00149 ;PMID: 30620668

Full text available

20
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Material Type:
Article
Add to My Research

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147 [Peer Reviewed Journal]

Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;Copyright © 2023 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2304594 ;PMID: 37272535

Full text available

Results 1 - 20 of 126,648  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (116,802)

Refine My Results

New Records 

  1. New From Last Week  (30)
  2. New From Last Month  (252)
  3. New From Last 3 Month  (1,040)
  4. More options open sub menu

Subject 

  1. Humans  (114,810)
  2. Science & Technology  (103,355)
  3. Life Sciences & Biomedicine  (98,308)
  4. Male  (57,793)
  5. Female  (57,398)
  6. Oncology  (46,882)
  7. Lung Neoplasms - Pathology  (44,622)
  8. Middle Aged  (43,701)
  9. Aged  (38,446)
  10. Lung Cancer  (36,534)
  11. Adult  (27,055)
  12. Lung Neoplasms - Drug Therapy  (25,822)
  13. Biological And Medical Sciences  (25,764)
  14. Lung Neoplasms - Genetics  (25,065)
  15. Medical Sciences  (24,710)
  16. Animals  (21,950)
  17. Tumors  (18,317)
  18. Respiratory System  (17,220)
  19. Lung Neoplasms - Metabolism  (16,773)
  20. Mice  (16,167)
  21. More options open sub menu

Language 

  1. English  (120,621)
  2. Japanese  (19,294)
  3. Chinese  (2,790)
  4. French  (1,235)
  5. German  (730)
  6. Spanish  (651)
  7. Portuguese  (576)
  8. Polish  (218)
  9. Korean  (204)
  10. Turkish  (152)
  11. Norwegian  (108)
  12. Russian  (100)
  13. Italian  (63)
  14. Swedish  (45)
  15. Czech  (34)
  16. Hungarian  (29)
  17. Croatian  (29)
  18. Serbian  (24)
  19. Icelandic  (20)
  20. Catalan  (11)
  21. More options open sub menu

Searching Remote Databases, Please Wait